Replimune Group Inc REPL

Healthcare Biotechnology

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

NDAQ:REPL - Post by User

Replimune Group Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jun 13, 2024 3:00pm

38 Views

Post# 36087714

Replimune Announces $100 Million Private Placement Financing

NEWS: $REPL Replimune Announces $100 Million Private Placement Financing- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...REPL - Replimune Announces $100 Million Private Placement Financing

<< Previous

Bullboard Posts

Next >>

TELUS adds 347K customers in Q3